Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 469Unknown 111Terminated 111Recruiting 105Active not recruiting 82Not yet recruiting 30Withdrawn 27Suspended 3Approved for marketing 2

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 2Gastrointestinal 1

Conditions

Breast Neoplasms 2Neoplasm Metastasis 1Colonic Neoplasms 1

Interventions

Specimen Handling 31Magnetic Resonance Spectroscopy 19Biopsy 16Cyclophosphamide 15Nivolumab 10Paclitaxel 9Vincristine 8Cisplatin 8venetoclax 7Prednisone 7Gemcitabine 7Doxorubicin 7Bevacizumab 7Azacitidine 7pembrolizumab 6Radiotherapy 6Fluorouracil 6Etoposide 6Drug Therapy 6Docetaxel 6Surgical Procedures, Operative 5Rituximab 5Radiosurgery 5Oxaliplatin 5Irinotecan 5Injections 5Everolimus 5Capecitabine 5fludarabine phosphate 4Taxes 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Suspended × Trastuzumab × Clear all
NCT05062889 2026-02-03

ERASE-CRC

Gruppo Oncologico del Nord-Ovest

Phase 2 Suspended
477 enrolled
Gastrointestinal

Colonic Neoplasms

NCT04120246 2024-07-10

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

Veana Therapeutics

Phase 1 Suspended
24 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02062983 2016-05-13

Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients

National Guard Health Affairs

Suspended
50 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡